Mounjaro Lawsuit: Why Mounjaro Fits the NAION Vision-Loss Track Only

Marin & MurphySuper Lawyers® 2014–2024(888) 348-2735

Ozempic (GLP-1) Lawsuit — Free Case Review

Which Medications — and Which Injuries — Qualify

Eligibility differs by drug and by injury track. Check yours against the current criteria in minutes.

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state.

Did this happen to you — or someone you love?

Start your free case reviewTell us anyway

Answered 24/7 · Free & confidential · No fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney's fee is a percentage of the gross recovery, calculated before expenses are deducted.

(888) 348-2735

Partners

Matthew T. Marin & Stefanie A. Murphy

Super Lawyers® honorees · American Association for Justice members

Ozempic inquiries get a personal review — and an honest answer either way, free and without obligation.

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state. Do not stop, start, or change any prescribed medication because of anything on this page. Those decisions belong with your prescriber. Attorney Advertising.

Mounjaro is Eli Lilly’s brand of tirzepatide, and under the current GLP-1 referral criteria it qualifies for the NAION sudden vision-loss track only — not for the stomach-injury track, which is limited to brand-name semaglutide (Ozempic, Wegovy, Rybelsus). Marin & Murphy is currently accepting Ozempic (GLP-1) NAION cases, and reviews Mounjaro stomach-injury inquiries individually rather than turning them away.

The track difference, stated plainly and up front

Most pages about GLP-1 lawsuits treat every one of these medications as interchangeable. They are not, and for Mounjaro users the difference is the whole story.

• NAION vision-loss track — Mounjaro qualifies. The referral criteria for non-arteritic anterior ischemic optic neuropathy cover brand-name Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, and Zepbound. A Mounjaro user with an actual NAION diagnosis and some degree of permanent vision impairment meets the drug criterion.
• Stomach-injury track — Mounjaro does not currently qualify. The gastroparesis and gastric-obstruction criteria are limited to brand-name semaglutide products. Mounjaro, Zepbound, and Trulicity do not meet them as written.

There is a nuance worth being straight about, because you will see it in the court documents. The Eastern District of Pennsylvania’s product list for the stomach-injury MDL does name Mounjaro, and Eli Lilly is an active defendant there. The litigation’s scope is broader than the intake criteria any given firm screens against — those criteria reflect how cases are currently being evaluated, not a ruling that Mounjaro stomach claims cannot exist. If you took Mounjaro and were hospitalized with a documented stomach injury, tell us; the answer may be a referral path rather than a case we take, and we will say which.

Where Mounjaro cases are litigated

Two federal proceedings, both in the Eastern District of Pennsylvania, both before Judge Karen S. Marston.

MDL 3163 (NAION vision loss) was created December 15, 2025, when the Judicial Panel on Multidistrict Litigation centralized 20 actions. The unusual part: the motion was filed by Eli Lilly itself on August 19, 2025, covering 21 actions, and granted over the objection of plaintiffs who preferred to stay where they were. Novo Nordisk filed in support. The proceeding grew from 20 pending actions to 216 as of the September 1, 2026 JPML report.

MDL 3094 (gastrointestinal injuries) was created February 2, 2024 and covers gastroparesis, ileus and intestinal obstruction, cholecystitis, and severe nausea and vomiting per Case Management Order No. 18. Eli Lilly is a defendant; a founding case, Smith v. Eli Lilly & Co., was filed in the Western District of Louisiana (No. 2:23-cv-01610) on November 9, 2023.

New Jersey runs a parallel structure: two multicounty litigations designated October 16, 2025, one gastrointestinal and one NAION, both in Bergen County before Judge Gregg A. Padovano, with Mounjaro named among the medications.

What the FDA adverse-event data shows for tirzepatide

As of the July 30, 2026 data refresh, FDA’s FAERS database held 160,663 total reports and 28,502 serious reports for tirzepatide, including 594 coded as intestinal obstruction, 291 for ileus, and 1,151 for visual impairment. Reports submitted to FDA are not verified and do not establish causation; they are voluntary, unvalidated, frequently duplicated, and heavily influenced by prescribing volume, media coverage, and litigation.

One honest observation about that data: the specific FAERS term used for NAION — optic ischaemic neuropathy — does not appear among tirzepatide’s top 200 reported reactions, while it appears 631 times for semaglutide. That difference is consistent with where the published research has concentrated, and it does not mean a Mounjaro NAION claim is unfounded. Raw report counts cannot be used to compare risk between drugs, and the referral criteria for the NAION track include Mounjaro precisely because the individual diagnosis, not the database, is what governs.

Who may qualify

• NAION (sudden optic-nerve vision loss) — the Mounjaro track: use of brand-name Mounjaro (or Ozempic, Wegovy, Rybelsus, Trulicity, Zepbound); an actual NAION diagnosis, made while taking the medication or after stopping; and some degree of permanent vision impairment. There is no age cutoff and no diagnosis-date cutoff in these criteria, and no emergency-room requirement.
• What helps a NAION review: the name of the eye doctor or neuro-ophthalmologist who made the diagnosis, whether giant-cell arteritis was ruled out, which eye was affected and when, your last dose date, and any record of what vision remains.
• Stomach injuries: the current criteria require brand-name semaglutide, so Mounjaro does not meet them. Tell us anyway if you were hospitalized — that goes to a review path, not a rejection.
• Compounded tirzepatide from a med spa or telehealth service does not meet the brand-name requirement in either track. Many people are unsure what they received; pharmacy records and packaging usually resolve it.
• You are not suing your doctor. These claims are against the manufacturer, Eli Lilly. Your prescriber and pharmacy are not targets, and the prescriber’s records are usually a claimant’s best evidence.

If you are looking this up for someone else

Many people reading a page like this are a spouse or an adult child, not the patient. NAION arrives suddenly, in one eye, usually without pain, most often to someone in their sixties, and the person it happened to often cannot comfortably read a page of small type on a phone. You do not need their permission to find out what the situation is, and asking questions on their behalf costs nothing and commits no one to anything.

Where the litigation stands today

The NAION proceeding is eight months old. On July 2, 2026, the court granted the defendants’ request to front-load general causation and preemption — the same structure used in the stomach-injury MDL — and directed the parties to propose a schedule and to exchange fact sheets and records confirming proof of use and proof of diagnosis. On July 21, 2026, the court appointed a special discovery master.

There is no expert schedule, no bellwether pool, and no trial date. In the older stomach-injury MDL, a Rule 702 hearing on general causation, preemption, and warning adequacy is underway September 14 through 18, 2026. Nothing has been decided on causation in either proceeding.

Common questions

Other GLP-1 medications: Wegovy, Rybelsus, Zepbound, Trulicity, and compounded semaglutide. The manufacturer: Eli Lilly.